Core Viewpoint - The stock of He Yu-B (02256) has seen a significant increase, with a rise of over 4% in the late trading session, currently up by 3.9% at HKD 14.13, with a trading volume of HKD 45.41 million [1] Group 1: Company Developments - He Yu announced that its subsidiary, He Yu Pharmaceutical, presented long-term efficacy, safety, and patient-reported outcome data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) at the CTOS 2025 conference [1] - The long-term analysis indicates that continuous treatment with pimicotinib can lead to sustained improvements in tumor response and further enhancements in patient-reported outcomes, including pain and function, while maintaining an acceptable safety profile [1] - The findings reinforce the long-term application potential of pimicotinib in suitable patients [1]
和誉-B尾盘涨超4% 公司展示匹米替尼临床III期MANEUVER研究长期疗效和安全性数据